How Do Doctors Choose Atezo/Bev vs STRIDE for HCC?

When deciding on a first-line systemic therapy (the initial medication that travels through the bloodstream to treat cancer) for advanced hepatocellular carcinoma (HCC), your oncology team will carefully weigh several options. Two of the most commonly used, guideline-supported options are Atezolizumab plus Bevacizumab (often called Atezo/Bev) and the STRIDE regimen (Durvalumab plus Tremelimumab) ^{[1] [2]}.

Both regimens have shown significant benefit in clinical trials ^{[2] [3] [4]}. However, because they were tested in separate trials rather than directly against each other, doctors cannot say one is universally “better” than the other ^[2]. Instead, your doctor will personalize the choice based on your specific health factors, including your liver function, bleeding risk, heart health, and future surgical plans.

Key Factors in Your Doctor’s Decision

To make the safest recommendation, your care team will evaluate your overall health, specifically looking at your Child-Pugh score—a medical grading system that estimates how well your liver is functioning. Both regimens are generally recommended for patients with well-preserved liver function (Child-Pugh A) and good overall daily functioning ^{[1] [5]}. If your liver is struggling (evidenced by severe jaundice, confusion, or fluid buildup in the abdomen), your team will proceed with extra caution.

1. Bleeding Risk and Varices

The most significant difference between the two treatments is the drug Bevacizumab. Bevacizumab is an anti-angiogenic therapy—it cuts off the blood supply to tumors. While effective, it also makes it harder for normal blood vessels to heal, increasing the risk of severe bleeding ^[6].

Many people with liver cancer also have cirrhosis, which can cause portal hypertension (abnormally high pressure in the vein leading to the liver) ^[5]. This pressure forces blood into smaller, fragile veins in the esophagus or stomach, creating swollen veins called varices ^[5]. If varices rupture, they can cause life-threatening internal bleeding, and bevacizumab increases this risk ^{[6] [7]}.

• How this affects your choice: Before starting Atezo/Bev, guidelines usually recommend an upper endoscopy to check for varices ^[8]. If small varices are found, they can often be treated (such as by “banding” them) before starting Atezo/Bev ^{[9] [7]}. However, if your varices are severe, untreated, or you have recently had major bleeding, your doctor may recommend the STRIDE regimen, which avoids the specific bleeding risks associated with bevacizumab ^[2].

2. Blood Pressure and Heart Health

Bevacizumab also affects the cardiovascular system. It can cause protein to leak into the urine (proteinuria) and is strongly linked to high blood pressure ^{[10] [11]}. In the IMbrave150 clinical trial, about 15% of patients taking Atezo/Bev developed severe (Grade 3 or 4) high blood pressure ^[10]. It also carries a slightly increased risk of blood clots ^[12].

• How this affects your choice: If you have difficult-to-control high blood pressure, a history of major arterial blood clots, or recent serious heart disease, your team may weigh this against Atezo/Bev. However, heart disease does not automatically rule out Atezo/Bev, and your doctor will evaluate your individual cardiovascular risk.

3. Immune System Side Effects

The STRIDE regimen uses a dual-immunotherapy approach (two drugs that activate your immune system to fight cancer). Because it avoids bevacizumab, STRIDE does not carry anti-angiogenic bleeding or blood pressure risks ^[2]. However, turning up the immune system means it can sometimes mistakenly attack healthy organs.

• How this affects your choice: Both regimens include immunotherapy and can cause severe immune-related side effects, such as colitis (severe intestinal inflammation), hepatitis (liver inflammation), and skin rashes ^{[13] [14]}. Very rarely, both regimens can cause severe heart muscle inflammation (myocarditis) ^{[15] [16]}. If you have a pre-existing autoimmune condition (like lupus or inflammatory bowel disease), your doctor will carefully evaluate whether immunotherapy is safe for you.

4. Surgery and Transplant Plans

If there is a possibility you will undergo major surgery, a liver-directed procedure (like tumor embolization), or a liver transplant, treatment timing is critical:

• Bevacizumab and Wound Healing: Bevacizumab impairs wound healing. It must be stopped well in advance of any surgery (often at least 28 days, depending on the procedure and your doctor’s protocol) and cannot be restarted until wounds are fully healed ^{[17] [18]}. Never stop or restart this medication without explicit instructions from your doctor.
• Immunotherapy and Transplants: All immunotherapy drugs carry a risk of increasing organ rejection. If you are being evaluated for a liver transplant, you must discuss this with a transplant center before starting either Atezo/Bev or STRIDE ^[19].

At-A-Glance Comparison

Urgent Warning Signs

No matter which regimen you and your doctor choose, side effects can occur during treatment or even months after it ends. Seek immediate medical attention if you experience:

• Signs of bleeding: Vomiting blood (or material that looks like coffee grounds), black or tarry stools, or sudden severe dizziness/fainting.
• Signs of immune toxicity: Severe diarrhea or abdominal pain, new chest pain or irregular heartbeat, severe shortness of breath, profound fatigue, or yellowing of your skin or eyes.